Join Growin Stock Community!

Anavex life sciences corp.AVXL.US Overview

US StockHealthcare
(No presentation for AVXL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AVXL AI Insights

AVXL Overall Performance

AVXL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AVXL Recent Performance

1.21%

Anavex life sciences corp.

-3.61%

Avg of Sector

-2.16%

S&P500

AVXL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AVXL Key Information

AVXL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AVXL Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Price of AVXL

AVXL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AVXL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.43
PE Ratio (TTM)
-
Forward PE
1.54
PS Ratio (TTM)
-
PB Ratio
3.26
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.43
PE Ratio (TTM)
-
Forward PE
1.54
PS Ratio (TTM)
-
PB Ratio
3.26
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is AVXL's latest earnings report released?

    The most recent financial report for Anavex life sciences corp. (AVXL) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AVXL's short-term business performance and financial health. For the latest updates on AVXL's earnings releases, visit this page regularly.

  • How much cash does AVXL have?

    At the end of the period, Anavex life sciences corp. (AVXL) held Total Cash and Cash Equivalents of 131.75M, accounting for 0.99 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is AVXL's EPS continuing to grow?

    According to the past four quarterly reports, Anavex life sciences corp. (AVXL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AVXL?

    Anavex life sciences corp. (AVXL)'s Free Cash Flow (FCF) for the period is -7.15M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 41% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AVXL?

    The latest valuation data shows Anavex life sciences corp. (AVXL) has a Price-To-Earnings (PE) ratio of -10.09 and a Price/Earnings-To-Growth (PEG) ratio of 0.33. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.